UPDATE 1-US FDA approves Opiant's spray for reversing opioid-related overdoses

Reuters2023-05-23

(Adds background in paragraph 3 and details on drug in paragraph 4)

May 22 (Reuters) - The U.S. Food and Drug Administration said on Monday it had approved Opiant Pharmaceuticals Inc's nasal spray for reversing opioid-related overdoses in adults and children aged 12 years and older.

The approval is expected to give a boost to British drugmaker Indivior Plc , which recently acquired the drug through its acquisition of Opiant in a deal worth $145 million.

It also expands treatment options to reverse opioid-related overdoses, which have claimed more than 100,000 lives in 2021, according to government estimates.

The spray, which will be sold under the brand name Opvee, is a nalmefene-based drug that acts more quickly and has longer-lasting effects when compared with naloxone, a commonly used medication for reversing opiod-related overdoses.

(Reporting by Bhanvi Satija, Vaibhav Sadhamta and Mariam Sunny in Bengaluru; Editing by Krishna Chandra Eluri and Anil D'Silva)

((Bhanvi.Satija@thomsonreuters.com; Outside U.S. +91 9873062788;))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2337606790?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2023-05-23 05:39","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2337606790","market":"us","top_or_hot":-1,"title":"UPDATE 1-US FDA approves Opiant's spray for reversing opioid-related overdoses","media":"Reuters","content":"<html><body><p>(Adds background in paragraph 3 and details on drug in paragraph 4)</p><p>      May 22 (Reuters) - The U.S. Food and Drug Administration said on Monday it had approved Opiant Pharmaceuticals Inc's nasal spray for reversing opioid-related overdoses in adults and children aged 12 years and older. </p><p>   The approval is expected to give a boost to British drugmaker Indivior Plc   , which recently acquired the drug through its acquisition of Opiant in a deal worth $145 million. </p><p>   It also expands treatment options to reverse opioid-related overdoses, which have claimed more than 100,000 lives in 2021, according to government estimates. </p><p>       The spray, which will be sold under the brand name Opvee, is a nalmefene-based drug that acts more quickly and has longer-lasting effects when compared with naloxone, a commonly used medication for reversing opiod-related overdoses. </p><p> (Reporting by Bhanvi Satija, Vaibhav Sadhamta and Mariam Sunny in Bengaluru; Editing by Krishna Chandra Eluri and Anil D'Silva)</p><p>((Bhanvi.Satija@thomsonreuters.com; Outside U.S. +91 9873062788;))</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>UPDATE 1-US FDA approves Opiant's spray for reversing opioid-related overdoses</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nUPDATE 1-US FDA approves Opiant's spray for reversing opioid-related overdoses\n</h2>\n\n<h4 class=\"meta\">\n\n\n2023-05-23 05:39 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1><strong>Reuters</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>(Adds background in paragraph 3 and details on drug in paragraph 4)      May 22 (Reuters) - The U.S. Food and Drug Administration said on Monday it had approved Opiant Pharmaceuticals Inc's nasal ...</p>\n\n<a href=\"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"OPNT","symbol_name":"Opiant Pharmaceuticals, Inc.","start_time":0,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","article_id":"2337606790","we_media_id":"1036604489","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2337606790","pubTimestamp":1684791576,"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1036604489","head_image":"https://static.tigerbbs.com/443ce19704621c837795676028cec868"},"summary":"(Adds background in paragraph 3 and details on drug in paragraph 4)      May 22 (Reuters) - The U.S.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"OPNT":"Opiant Pharmaceuticals, Inc.","BK4007":"制药"},"translate_title":"更新1-美国FDA批准Opiant的喷雾剂用于逆转阿片类药物相关的过量用药","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"OPNT":0.9},"content_text":"(Adds background in paragraph 3 and details on drug in paragraph 4)      May 22 (Reuters) - The U.S. Food and Drug Administration said on Monday it had approved Opiant Pharmaceuticals Inc's nasal spray for reversing opioid-related overdoses in adults and children aged 12 years and older.    The approval is expected to give a boost to British drugmaker Indivior Plc   , which recently acquired the drug through its acquisition of Opiant in a deal worth $145 million.    It also expands treatment options to reverse opioid-related overdoses, which have claimed more than 100,000 lives in 2021, according to government estimates.        The spray, which will be sold under the brand name Opvee, is a nalmefene-based drug that acts more quickly and has longer-lasting effects when compared with naloxone, a commonly used medication for reversing opiod-related overdoses.  (Reporting by Bhanvi Satija, Vaibhav Sadhamta and Mariam Sunny in Bengaluru; Editing by Krishna Chandra Eluri and Anil D'Silva)((Bhanvi.Satija@thomsonreuters.com; Outside U.S. +91 9873062788;))","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.3","shortVersion":"4.29.3","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2337606790"}